Theres uncertainty around the effectiveness of microdosing compounded versions of GLP-1s and a lack of research on the safety of this method
But this exclusion remains embedded in permanent Part D law after the Bridge expires, the structural barrier returns unless Congress acts
In most cases, adults may qualify for GLP-1 weight loss medications with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition such as high blood pressure, type 2 diabetes, prediabetes, high cholesterol, sleep apnea, or cardiovascular disease
Dose reduction or discontinuation may be necessary if you develop: Persistent, intolerable gastrointestinal symptoms despite supportive measures Acute pancreatitis (discontinue permanently) Severe hypoglycemia, particularly if taking concurrent insulin or sulfonylureas Acute kidney injury or worsening renal function Gallbladder disease symptoms (abdominal pain, jaundice) Diabetic retinopathy complications (particularly with semaglutide) Severe hypersensitivity reactions including anaphylaxis or angioedema Pregnancy or plans for pregnancy (for semaglutide, discontinue at least two months before planned conception
These medications have been costing employers between $617 and $766 per fill through traditional insurance channels
Oral Semaglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes
